COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03856099




Registration number
NCT03856099
Ethics application status
Date submitted
21/02/2019
Date registered
27/02/2019
Date last updated
14/04/2020

Titles & IDs
Public title
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
Scientific title
A Multicenter, Open-Label, Phase ? Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
Secondary ID [1] 0 0
PMC_TTAC-0001_03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Recurrent Glioblastoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TTAC-0001

Experimental: TTAC-0001 - TTAC-0001 with dose assigned to each dose group will be administered


Treatment: Drugs: TTAC-0001
Investigational product (IP): TTAC-0001
Treatment groups: 3 dose groups
Dose group A : TTAC-0001 16 mg/kg on D1 and D15
Dose group B : TTAC-0001 20 mg/kg on D1 and D15
Dose group C : TTAC-0001 24 mg/kg on D1 and D15
Cycle: 4 weeks (28 days per cycle)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse Events - The frequency and percentage of AEs will be presented by dose goup
Timepoint [1] 0 0
until time of progressive disease or 1 year
Secondary outcome [1] 0 0
Progression free survival rate at 4 months - The rate and 2-sided 95% confidence interval of progression free survival at the 4-month
Timepoint [1] 0 0
at the end of 4 months
Secondary outcome [2] 0 0
Progression free survival rate at 6 months - The rate and 2-sided 95% confidence interval of progression free survival at the 6-month
Timepoint [2] 0 0
at the end of 6 months
Secondary outcome [3] 0 0
Progression free survival - Period from the date of the drug administration to the disease progression time point
Timepoint [3] 0 0
until time of progressive disease or time point of patients' death which come first assessed up to 1 year
Secondary outcome [4] 0 0
Overall survival - Period from the date of the drug administration to the time point of patient's death
Timepoint [4] 0 0
until time point of patients' death up to 1 year
Secondary outcome [5] 0 0
Objective response rate - complete response (CR) or partial response (PR) by RANO criteria
Timepoint [5] 0 0
At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)
Secondary outcome [6] 0 0
Disease control rate - complete response (CR), partial response (PR) or stable disease (SD) by RANO criteria
Timepoint [6] 0 0
At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)

Eligibility
Key inclusion criteria
1. Provision of signed and dated informed consent prior to any study specific procedures,
sampling or analyses.

2. Aged at least 18 years old

3. Patients must have a histologically proven diagnosis of glioblastoma/gliosarcoma

4. Patients must have previous treatment including bevacizumab

5. Patients must have a radiological diagnosis of recurrent/relapsed or progressive
glioblastoma/gliosarcoma after bevacizumab including therapy according to response
assessment in neuro-oncology (RANO) criteria

6. At least one confirmed measurable lesion or non measurable lesion as determined by
RANO criteria

7. Patients must undergo IDH1 mutational testing on a tumor specimen before entering the
study. Immunohistochemistry (IHC) is sufficient for enrollment, although DNA
sequencing may also be performed as per local institutional guidelines. Patients are
eligible regardless of their tumor status.

8. Karnofsky Performance Status (KPS) = 70

9. A person who satisfies the following criteria in hematologic, renal, and hepatic
function tests (1) Hematologic tests - Absolute neutrophil count (ANC) = 1.5 x 109/L -
Platelets = 75 x 109/L

- Hemoglobin = 9.0 g/dL (2) Blood coagulation tests

- Prothrombin time (PT) = 1.5 x Upper limit of normal (ULN)

- Activated partial thromboplastin Time (aPTT) = 1.5 x ULN (3) Hepatic function tests

- Total bilirubin = 1.5 x ULN

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 3 x ULN (4)
Renal function test

- Creatinine clearance (CrCl) = 30 mL/minute calculated by Cockcroft-Gault formula

10. Life expectancy of at least 12 weeks

11. Females of child bearing potential must have a negative pregnancy test during
screening and must not be breastfeeding or intending to become pregnant during the
study.

12. Male patients with female partners of child-bearing potential must be willing to use
two forms of acceptable contraception, including one barrier method, during their
participation in this study and for 16 weeks following the last dose of the study.
Refer to section 10.5.1 Restrictions, permitted methods of contraception and
definitions.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diagnosed with malignant tumors, except basal cell carcinoma, cutaneous squamous cell
carcinoma, and noninvasive uterine cervical cancer treated within 2 years prior to
receiving the first dose of treatment.

2. The following concomitant diseases:

(1) Uncontrolled hypertension (systolic blood pressure [SBP] > 150 or diastolic blood
pressure [DBP] > 90 mmHg) (2) Uncontrolled seizures (3) Class III or IV heart failure
according to New York Heart Association (NYHA) classification (4) Oxygen-dependent chronic
disease (5) Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
disorder etc.). Treated depression with ongoing antidepressant medication is not an
exclusion.

3) Not recovered from AEs < National Cancer Institute -Common Terminology Criteria for
Adverse Events (NCI-CTCAE) grade 2 caused by CCRT 4) Treatment with bevacizumab including
therapy 2 weeks prior to receiving the first dose of treatment.

5) Undergone major surgery requiring general anesthesia or a respiratory assistance device
within 4 weeks prior to the baseline visit (within 2 weeks for video-assisted thoracoscopic
surgery [VATS] or open-and-closed [ONC] surgery) 6) Treated with other investigational
products within 4 weeks prior to the patient receiving the first dose of treatment.

7) A known history of severe drug hypersensitivity or hypersensitivity to a therapy similar
to the study drug 8) Unable to participate in the trial according to the investigator's
decision. 9) Patient not eligible for sequential MRI evaluations are not eligible for this
study 10) Previous therapy with VEGF-targeted agents except bevacizumab. 11) Known active
hepatitis B or hepatitis C infection 12) Has received a live vaccine within 30 days prior
to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.

13) Has had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to
enrollment

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
PharmAbcine
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of
TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including
therapy.
Trial website
https://clinicaltrials.gov/show/NCT03856099
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Seonyoung Lee, MPH
Address 0 0
Country 0 0
Phone 0 0
+8210-4360-2257
Fax 0 0
Email 0 0
sylee@pharmabcine.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03856099